As reported by Outsourcing Pharma, Parexel and Icon will be providing the US pharma company, Pfizer, with clinical development services as part of a five-year agreement that will begin next month. This marks the latest of a number of strategic partnerships by CRO’s.
Speaking of the agreement, Parexel CEO Josef von Rickenback stated, “Pfizer has engaged Parexel in a strategic partnership model and we have been selected as one of only two strategic partners that will handle their clinical development needs over the next five years.”
“Parexel will leverage its proven clinical processes and expertise combined with its market-leading eClinical technology platform. This will help Pfizer gain greater visibility into trials and improve data access for faster, better decision making.”